In our final set of experiments, we demonstrated that the proposed gene‐editing approach was capable of correcting the phenotype of hematopoietic CD34+ cells from FA‐A patients, showing for the first time the possibility of conducting therapeutic gene editing in HSPCs from patients with a syndrome characterized by bone marrow failure and DNA repair defects. The gene discussed is CD34; the disease is Friedreich ataxia.